• Publications
  • Influence
Evidence of brain tumor stem progenitor-like cells with low proliferative capacity in human benign pituitary adenoma.
Tumor stem cells have been implicated as cancer-initiating cells in malignant brain tumors. However, whether benign brain tumors also contain tumor stem cells are largely unexplored. Here, weExpand
  • 23
  • 5
Bromocriptine treatment of invasive giant prolactinomas involving the cavernous sinus: results of a long-term follow up.
OBJECT The aim of this study was to observe long-term clinical outcomes in a group of patients treated with bromocriptine for invasive giant prolactinomas involving the cavernous sinus. METHODSExpand
  • 69
  • 3
  • PDF
Natural History of Postoperative Nonfunctioning Pituitary Adenomas: A Systematic Review and Meta-Analysis
Objective: Previous studies attempting to define the natural history of postoperative nonfunctioning pituitary adenomas (pNFPAs) were somewhat limited by selection bias and/or small numbers and/orExpand
  • 55
  • 3
Activation of DRD5 (dopamine receptor D5) inhibits tumor growth by autophagic cell death
ABSTRACT Dopamine agonists such as bromocriptine and cabergoline have been successfully used in the treatment of pituitary prolactinomas and other neuroendocrine tumors. However, their therapeuticExpand
  • 39
  • 3
Suppression of mTOR pathway and induction of autophagy-dependent cell death by cabergoline
Cabergoline (CAB), the first-line drug for treatment of prolactinomas, is effective in suppressing prolactin hypersecretion, reducing tumor size, and restoring gonadal function. However, mechanismsExpand
  • 22
  • 3
  • PDF
Radical Resection of 202 Pediatric Craniopharyngiomas with Special Reference to the Surgical Approaches and Hypothalamic Protection
Objective: The goal of this study was to disclose the appropriate surgical approaches to radically removing pediatric craniopharyngiomas with optimal hypothalamic protection. Methods: In 202 patientsExpand
  • 60
  • 2
microRNA expression profile and differentially-expressed genes in prolactinomas following bromocriptine treatment.
Little is known about the function of microRNAs in prolactinomas treated with bromocriptine. The aim of the study was to explore the microRNAs associated withExpand
  • 26
  • 2
  • PDF
Cordycepin confers neuroprotection in mice models of intracerebral hemorrhage via suppressing NLRP3 inflammasome activation
Neuroinflammation has been recognized as a major contributor to brain injury caused by intracerebral hemorrhage (ICH). Nucleotide-binding oligomerization domain-like receptor family pyrinExpand
  • 21
  • 2
Posterior petrous meningiomas: 82 cases.
OBJECT The aim of this study was to discuss posterior petrous meningiomas--their classification, clinical manifestations, surgical treatments, and patient outcomes. METHODS A retrospective analysisExpand
  • 34
  • 1
  • PDF
Pituitary Tumor Suppression by Combination of Cabergoline and Chloroquine
  • S. J. Lin, Z. Wu, +7 authors Z. Wu
  • Medicine
  • The Journal of clinical endocrinology and…
  • 1 October 2017
Context The dopamine agonist cabergoline (CAB) has been used widely in the treatment of prolactinomas and other types of pituitary adenomas, but its clinical use is hampered by intolerance in someExpand
  • 17
  • 1